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ABSTRACT 
 
The extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein (MAP) kinase pathway has 
been involved in the positive and negative regulation of cell proliferation. Upon mitogen stimulation, 
ERK1/ERK2 activation is necessary for G1- to S-phase progression whereas when hyperactived, this 
pathway could elicit cell cycle arrest. The mechanisms involved are not fully elucidated but a kinase-
independent function of ERK1/2 has been evidenced in the MAPK-induced growth arrest. Here, we show 
that p70S6K, a central regulator of protein biosynthesis, is essential for the cell cycle arrest induced by 
overactivation of ERK1/2. Indeed, whereas MEK1 silencing inhibits cell cycle progression, we demonstrate 
that active mutant form of MEK1 or MEK2 triggers a G1 phase arrest by stimulating an activation of 
p70S6K by ERK1/2 kinases. Silencing of ERK1/2 activity by shRNA efficiently suppresses p70S6K 
phosphorylation on Thr421/Ser424 and S6 phosphorylation on Ser240/244 as well as p21 expression, but 
these effects can be partially reversed by the expression of kinase-dead mutant form of ERK1 or ERK2. In 
addition, we demonstrate that the kinase p70S6K modulates neither the p21 gene transcription nor the 
stability of the protein but enhances the translation of the p21 mRNA. In conclusion, our data emphasizes 
the importance of the translational regulation of p21 by the MEK1/2-ERK1/2-p70S6K pathway to 
negatively control the cell cycle progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Within the MAPK (Mitogen-Activated Protein Kinase) superfamily, the Raf/MEK/ERK pathway plays a 
pivotal role in the regulation of numerous physiological processes ranging from proliferation to cell 
motility, differentiation and cell survival (Shaul and Seger, 2007). In recent years, various mechanisms 
have been proposed in order to explain the signal specificity of MEK/ERK responses. These include the 
regulation of signal duration and intensity, the kinase subcellular localization and cross-talks with other 
signaling pathways (Murphy and Blenis, 2006). The existence of different components at each level of the 
pathway could also participate in the signal specificity (Wortzel and Seger, 2011). Human cells express 
three different Raf isoforms (A-Raf, B-Raf and C-Raf), three MEK (MEK1, MEK2, MEK1b) and three 
ERK isoforms (ERK1, ERK2, ERK1c). While specific functions have been assigned to MEK1b and 
ERK1c in Golgi fragmentation and mitotic progression (Shaul et al., 2009), ERK1/ERK2 or MEK1/MEK2 
isoforms have been considered for a long time as fully redundant proteins because of their high sequence 
homology and substantially equivalent spatiotemporal regulations. 
However, these kinases could also perform specific functions in specific contexts. For instance, ERK2 but 
not ERK1 could regulate the EMT transition of MCF10A cells or the 3D migration of MDA-MB-231 
breast cancer cells (Shin et al., 2010; von Thun et al., 2012). In contrast, ERK1 but not ERK2, appeared to 
be the main regulator of normal or transformed hepatocyte survival (Fremin et al., 2012; Guegan et al., 
2013). Nevertheless, the notion of functional specificity between these isoforms remains controversial. As 
demonstrated in the proliferation of fibroblasts, the apparent specificities could only be a simple reflection 
of the predominant expression of one isoform over the other (Lefloch et al., 2007; Voisin et al., 2010). 
Given its implications in the regulation of cell survival and proliferation, pro-oncogenic functions of the 
MEK/ERK pathway have been demonstrated both in vitro and in vivo (Kim and Choi, 2010; Malumbres 
and Barbacid, 2003). Aberrant activation of this pathway, resulting from the expression of active mutants 
of Ras, Raf or MEK1/2, induced the in vitro transformation of fibroblasts or epithelial cells (Brunet et al., 
1994; Cowley et al., 1994; Voisin et al., 2008) as well as the hypertrophy of different tissues in vivo (Bueno 
et al., 2000; Scholl et al., 2004). Paradoxically, sustained activation of the Ras/Raf/MEK/ERK pathway can 
also induce senescence and/or growth arrest in different normal cells such as primary fibroblasts, T-cells or 
hepatocytes (Chen et al., 1999; Serrano et al., 1997; Sewing et al., 1997; Tombes et al., 1998). This growth 
arrest can also be found in different tumor cell lines, generally derived from tumors where Ras/Raf 
mutations are rare, like glioma, prostate carcinoma, medullary thyroid carcinoma, small cell lung 
carcinoma or rhabdomyosarcoma (Ciccarelli et al., 2005; Hong et al., 2009; Ravi et al., 1998). This 
antagonistic control of the cell cycle by the ERK pathway has been postulated to represent an important 
tumorigenesis barrier whose physiological importance has been demonstrated in vivo by 
the observation of cellular senescence in pre-malignant lesions (Collado et al., 2005; Michaloglou et al., 
2005). Heretofore, various intermediate pathways have been shown to participate in the Ras/Raf-induced 
growth arrest, like p38/PRAK, Wnt or JAK/STAT pathways (Park et al., 2003; Sun et al., 2007; Ye et al., 
2007). However, our knowledge of the molecular mechanisms specifically regulated by the MEK/ERK 
kinases remains quite limited. And yet, a precise characterization of this key mechanism against 
tumorigenesis could be useful to elicit the development of new therapeutic strategies to suppress tumor 
growth. The MEK/ERK-induced growth arrest has been associated with the expression of various cell cycle 
regulators such as induction of the p53 tumor suppressor or different cell cycle inhibitors like 
p27KIP1,p21WAF1 or p16INK4a (Lin et al., 1998; Ravi et al., 1998; Zhu et al., 1998). Whereas their 
involvements are dependent on the cellular context, the expression of p21WAF1 seems to be a more general 
event and has been found in p53-dependent and independent mechanisms (Lee et al., 1999; Olsen et al., 
2002; Sewing et al., 1997; Woods et al., 1997). ERK1/2 kinases could increase p21 expression by  
 regulating different transcription factors such as Sp1, Ets1/2 or C/EBPα-β (Park et al., 2000; Vaque et al., 
2005). Whereas this role required a kinase function of ERK, a non-catalytic function of the proteins was 
recently highlighted in the regulation of p21 expression. However, the mechanisms by which ERK inactive 
mutants induces growth arrest have not been elucidated (Hong et al., 2009). 
In this study, we aimed to elucidate the mechanisms involved in the MEK/ERK-induced growth arrest. As 
a model, we used the Huh-7 cell line derived from a human hepatocellular carcinoma, a malignancy where 
Ras/Raf mutations are rare. By performing transient expression of active forms of MEK1 or MEK2, we 
showed that aberrant activation of the MEK/ERK pathway induced a G1-phase arrest. We demonstrated 
that ERK1 and ERK2 both stimulated the expression of p21 in a redundant and non-catalytic manner by 
stimulating the phosphorylation of p70S6K on Thr421/Ser424 and the subsequently cap-dependent 
translation of p21. This model has been proved in both liver and breast cancer cells. 
  
MATERIALS AND METHODS 
 
Cell culture and reagents- The human hepatocellular carcinoma cell lines Huh-7D12 and HepG2, as well 
as the human breast cancer cells MCF-7, were maintained in DMEM 4.5 g/L glucose supplemented with 
10% FCS, penicillin (20 UI/ml) and streptomycin (20 µg/ml). 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), cyclosporine A, cycloheximide and the PDK1 inhibitor GSK2334470 
(GSK) were from Sigma Aldrich (St Quentin Fallavier, France). The inhibitors GF109203X (GFX) and 
Wortmannin were from Calbiochem (VWR, Fontenay-sous-Bois, France). The inhibitor Rapamycin and 
the antibodies raised against P-Akt, P-ERK1/2 (Thr202/ Tyr204), P-JNK, p21, P-p38, P-p70S6K (Thr389), 
Pp70S6K (Thr421/ Ser424), p70S6K , P-S6 (Ser240/244), P-4E-BP1 (Ser65), 4E-BP1, mTOR, cyclin D1, 
cyclin E2, cyclin A2, cyclin B1, p27, p53 and P-p90 RSK were purchased from Cell Signaling (Ozyme, 
Saint-Quentin-en-Yveline, France). The antibody anti-human Rb (clone G99-2005) was from BD 
bioscience (Le Pont de Claix, France). Polyclonal antibodies against ERK1 (sc-94), ERK2 (sc-154), HA 
(sc-805), MEK1 (sc-219), MEK2 (sc-524), p16 (sc1661),c-Myc (sc-40) and Hsc- 70 (sc-7298) were from 
Santa Cruz Biotechnology (Heidelberg, Germany). Secondary antibodies conjugated to horseradish 
peroxidase were obtained from Dako (Trappes, France). 
 
Transfection and RNA interference experiments- Small hairpin RNAs (shRNA) targeting human MEK1, 
MEK2, ERK1, ERK2, P70S6K and mTOR as well as scramble sequence were provided by the company 
Transat (Lyon, France). Sequences were vector-inserted into the pRetro-SUPER plasmid expressing the 
puromycin resistance gene (Screeninc, Amsterdam, Netherlands). DNA Plasmids pCMV HA-MEK1 wild 
type (MEK1-WT), K97A (MEK1-K) and S218D/S222D (MEK1-DD), pCMV HA-MEK2 wild type 
(MEK2-WT), K101A (MEK2-K) and S222D/S226D (MEK2-DD) and the plasmid His-p21 were kindly 
provided by Dr. Sylvain Meloche (Institute for Research in Immunology and Cancer, Montréal, Canada). 
MEK1- DD and MEK2-DD are constitutively active and MEK1-K and MEK2-K are the dominant negative 
forms of MEK1/2. The plasmids pCMV-ERK1 K71R and pCMV-ERK2 K52R, the dominant-negative 
forms, were nicely provided by Dr. Peter Shaw (University of Nottingham, UK). DNA transfections were 
carried out using XtremeGene 9 DNA transfection reagent (Roche, Meylan, France) according to the 
manufacturer’s instructions. Briefly, cells were plated in a 35 mm-petri dish. After an overnight incubation, 
2 µg of shRNA plasmid (carrying puromycin resistance gene) or pBABE-puro vector + 1µg of expression 
plasmid were mixed with 5 µl of XtremeGene 9 DNA (Roche) and then added to the cells. For transient 
transfections, cells were selected during 24h by puromycin (4.5 µg/ml) and cyclosporine (5µM) as 
described (Lefloch et al., 2007). For stable cell line generation, transfected cells were selected during 1 
month with puromycin (2 µg/ml) and cultured under selection pressure as described (Guegan et al., 2013). 
 
Proliferation assays- To measure proliferation, 2500 cells were seeded in 96-well plate. At indicated time, 
cell number was determined using colorimetric MTT assay. Briefly, cells were incubated with 0.5 mg/ml of 
MTT for 2h at 37°C and formazan cristals were dissolved in DMSO. Absorbance was measured at 550nm 
on Spectramax microplate reader (Molecular Devices, Wokingham, UK). Background absorbance at 690 
nm was subtracted. A proliferation index was then calculated as the absorbance ratio of cells at indicated 
time to absorbance at day 1, and expressed as relative units (RU). Proliferation inhibition was calculated 
using the formula (1- ((proliferation index of cells) / (proliferation index of control cells))) and expressed as 
percentage. 
 
Reverse transcriptase and polymerase chain reactions- Total RNAs were extracted from Huh-7 cells using 
the kit NucleoSpin RNA II (Macherey-Nagel, Hoerd, France). Concentrations of total RNA were measured 
on NanoDrop ND-100 (NanoDrop Technologies, Wilmington, DE) and 1µg of RNA was subjected to a 
reverse transcription reaction using the High Capacity cDNA Reverse Transcription kit from Applied 
Biosystems (Foster City, CA). Real-time quantitative polymerase chain reaction (qPCR) was performed 
using SYBR Green PCR Master Mix (Applied Biosystems) on the ABI Prism 7700 Sequence Detector 
System (Applied Biosystems). All reactions were conducted according to manufacturer’s instructions. 
Fold inductions of p21 mRNA were calculated according to the 2-∆∆ct method. Primer sequences were as 
follows: CDKN1A 5’-CTGGAGACTCTCAGGGT CG-3’ (Fwd) and 5’-CGGCGTTTGGAGTGGTA GA-
3’ (Rev); 18S RNA 5’- CGGCTACCACATCC AAGGAA-3’ (Fwd) and 5’-GCTGGAATTACCG 
CGGCT-3’ (Rev). 
 Immunoblots- To extract total proteins, cells were washed once with phosphate-buffered saline and then 
lysed in a buffer containing 15mM p-nitrophenylphosphate, 15mM MgCl2, 25mM MOPS pH 7.2, 15mM 
EGTA, 60mM β-glycerophosphate, 2mM DTT, 1mM orthovanadate, 1mM NaF, 1mM phenylphosphate, 
100 mM benzamidin and 1X of Complete protease inhibitor cocktail (Roche). 20 µg of total cell extract 
were resolved on 6,5-12% SDS-PAGE and transferred onto nitrocellulose membrane for 1h using a 
TransBlot TM cell apparatus (Biorad, Marnes-la-coquette, France). Membranes were incubated overnight 
at 4°C with appropriate primary antibody and then with HRP-conjugated secondary antibody for 1h at 
room temperature. Immunoblots were analyzed on the Fujifilm LAS-3000 imager (Fujifilm, Tokyo, Japan). 
Densitometric analyses were performed on the MultiGauge software (Fujifilm) or on the ImageJ software 
(National Institutes of Health). 
 
Statistical analysis- Results are expressed as the mean ± standard deviation (SD). Data were analyzed with 
two-tailed Student t test. Differences were considered significant when P<0.05 (*) and P<0.01(**). All 
experiments were performed at least three times. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Sustained ERK activity alters Huh-7 cell proliferation- In order to study the involvement of the MEK/ERK 
pathway in the regulation of Huh-7 cell proliferation, we first transiently expressed different mutant forms 
of MEK1 or MEK2 and analyzed the proliferative capacity of transfected cells by MTT assay. As shown in 
Figure 1, differences in Huh-7 proliferation appeared according to the activity of expressed MEK1 or 
MEK2-WT (wild-type), -K (dominant negative) and – DD (constitutively active). Indeed, wild-type MEK1 
or MEK2 expression did not modify the proliferative capacity of the cells or the level of ERK1/2 basal 
activation. However, when active form of MEK1 or MEK2 was expressed, Huh-7 cells exhibited a 
sustained activation of ERK1/2 kinases and a reduced proliferation (Figure 1). In those cells, ERK activity 
was comparable to that obtained after a constant EGF stimulation (Supplementary Figure 1). Moreover, it is 
to note that no cell death or apoptosis engagement was detected in MEK1/2-DD expressing cells (data not 
shown). A high ERK activity, mediated by constitutively active form of MEK1 or MEK2, could thus be 
sufficient to impede the proliferation of human hepatocellular carcinoma cells. 
Interestingly, we observed that the dominant negative form of MEK1 slowed down the growth of Huh-7 
cells while the inactive form of MEK2 had no impact on it. This is consistent with our previous 
demonstration, both in vitro and in vivo, that MEK1 was specifically involved in the proliferation of 
hepatocellular carcinoma cells (Gailhouste et al., 2010). Indeed, as shown in Figure 2A, Huh-7 cells stably 
knocked-down for MEK1 exhibited a decreased proliferation rate compared to control cells. On the 
contrary, MEK2 silencing did not alter the growth of Huh-7 cells even if it decreased basal ERK1/2 
activation similarly to MEK1. Recently, two different groups have shown that the apparent functional 
specificity observed between ERK1 and ERK2 in fibroblast proliferation was only due to the predominant 
expression of ERK2. As a consequence, ERK1 invalidation did not impact on ERK1/2 total activity as 
ERK2 deletion did and thus had less effects on proliferation (Lefloch et al., 2007; Voisin et al., 2010). 
Hence, to ascertain that the MEK2 kinase was not involved in Huh-7 cell proliferation, we tried to rescue 
the phenotype of MEK1-targeted cells by expressing wild-type form of the kinase MEK1 or MEK2. In 
MEK1 silenced cells, an inhibition of cell proliferation was seen and the proliferation could be rescued by 
the overexpression of MEK1 in silenced cells (shMEK1+ pMEK1-WT) (Figure 2B). On the contrary, 
MEK2-WT expression failed to counterbalance the loss of MEK1 despite the high expression of the kinase 
MEK2 (Figure 2C). In order to ensure that the MEK2 inability to rescue was not caused by an insufficient 
activity, we tried to restore the proliferation of MEK1 silenced cells by expressing the active form of 
MEK2 (MEK2-DD). As shown in Figure 2C, expression of constitutively active MEK2 induced a high 
level of ERK1/2 activity but also failed to rescue the cell proliferation. Unexpectedly, the expression of the 
active form of MEK1 did not act as an improved version of wild-type MEK1 as the proliferation defect was 
not rescued anymore. In contrast, MEK1-DD amplified the inhibition of proliferation triggered by the loss 
of MEK1 (Figure 2B). Hence, all these data indicate that MEK1, but not MEK2, could be specifically 
required for inducing the proliferation of human transformed hepatocytes. However, an “over” ERK1/2 
activity, induced either by the active forms of MEK1 or MEK2, can be sufficient to mediate a growth arrest 
in human hepatocellular carcinoma cells. 
 
ERK1/2 sustained activity induces p21 expression in a redundant and kinase-independent manner - The 
Raf/MEK/ERKmediated growth arrest has been shown to be associated with the regulation of various 
proteins, depending on the cellular context. Thus, we next tried to characterize the mechanisms involved in 
the proliferation inhibition of Huh-7 cells. As shown in Figure 3A, expression of active form of MEK1 or 
MEK2 induced a high ERK1/2 activation and resulted in a G1 phase arrest, as observed by the increased 
level of cyclin D1, the reduced expressions of others cyclins (e.g. Cyclin A2, E and B1) and the 
unphosphorylated status of the kinase cdc2, which is naturally phosphorylated on Tyr15 in the S- and G2- 
phases of the cell cycle (Norbury et al., 1991). We also noticed that the G1 phase arrest seemed to be 
dependent on p21WAF1 expression as the expression level of the cell cycle inhibitor was greatly increased in 
MEK1/2-DD expressing cells, contrarily to p27KIP1, whose level was not altered, or p16INK4A which 
presented a reduced expression. Moreover, similar induction of p21 was observed in MEK1-silenced cells 
expressing MEK2-DD (data not shown). This p21 massive expression should be sufficient to inhibit 
cdk4/6-cyclin D activities as indicated by the reduced retinoblastoma protein (Rb) phosphorylation (Figure 
3A). However, to ascertain that p21 persistent expression could regulate the growth of transformed 
hepatocytes, we next induced an ectopic expression of p21 in Huh-7 cells and analyzed their proliferation. 
MTT assays revealed that cell growth was greatly impaired by the mere presence of p21WAF1 (Figure 3B). 
Moreover, p21 over-expression inhibited Huh-7 proliferation to a similar extent as compared to the 
constitutive activation of MEK1 or MEK2 (Figure 3C), which suggested that the growth arrest induced by 
high MEK/ERK activity could rely on p21 action. As a consequence, we used, in the rest of this study, the 
expression of p21 as a surrogate marker to analyze the mechanisms implied in MEK/ERK-mediated growth 
arrest. We next investigated whether the cytostatic signal was mediated specifically or not by ERK1 or 
ERK2. For this purpose, we transiently silenced by shRNA each of the kinases in cells harboring an active 
form of MEK1 or MEK2. As shown in Figure 4A, p21 induction by MEK1-DD or MEK2-DD was just 
slightly decreased by the loss of ERK1 whereas it was completely abolished in cells silenced for ERK2. 
Consistently, cells knocked-down for ERK2 were less subjected to the antiproliferative effect triggered by 
MEK1/2-DD over-expression in contrast to shERK1 or control cells (Figure 4B). To test if 
the growth arrest specifically relied on ERK2, we next inhibited endogenous ERK1 or ERK2 activity by 
expressing dominant-negative forms of ERK1 (K71R) or ERK2 (K52R) in Huh-7 cells and analyzed the 
induction of p21 upon MEK activation. In contrast with shRNA-based experiments, the inhibition of ERK1 
or ERK2 by the kinase-dead form could not prevent the expression of the cell cycle inhibitor induced by 
active MEK. Nevertheless, the dominant negative mutants efficiently reduced both basal and induced p90 
RSK activation (an ERK1/2 substrate used here as a read-out for in vivo ERK kinase activity) (Figure 4C). 
Next, we tried to rescue p21 expression in shERK2 cells using the kinase-dead form of ERK1 or 
ERK2. As shown in Figure 4D, ERK1 K71R as well as ERK2 K52R could both partially restore p21 
induction upon MEK activation, while inhibiting endogenous ERK activities. Hence, ERK1 and ERK2 
could both inhibit the proliferation of Huh-7 cells by increasing p21 level, in a redundant and kinase 
independent manner. 
 
p70S6K is required for the growth arrest induced by the MEK/ERK pathway- To get further insight in the 
mechanisms associated with MEK/ERK-induced growth arrest, we analyzed whether other signaling 
pathways were modified by MEK1 or MEK2 constitutive activation. In MEK1-DD or MEK2-DD Huh-7 
cells, no activation or inhibition of the PI3K-, JNK- and p38 pathways was noticed (Figure 5A). 
Nevertheless, an important phosphorylation of the kinase p70S6K (70-Kda S6 kinase) could be seen on 
residues Thr421 and Ser424, what led to a slight increase in the Thr389 phosphorylation. Phosphorylation 
of its S6 substrate on ser 240/244 was also greatly induced by constitutive activation of MEK1 or MEK2. 
To test the importance of p70S6K activation during the growth arrest, we compared the phosphorylation 
status of this kinase in control or in ERK2-silenced cells, which are less prone to the proliferation inhibition 
(Figure 5B). In those cells, phosphorylations of p70S6K on Thr421/Ser424 and S6 on Ser 240/244 were 
strikingly reduced. The increased phosphorylation of the Thr389 residue was also lost by the silencing of 
ERK2. Interestingly, we did not find major modifications in the phosphorylation of the 4E-BP1 protein, 
another mTOR target, between shCtl or shERK2 cells upon MEK1/2 overactivation. The residues Thr421 
and Ser424 of p70S6K are located in a full consensus site of phosphorylation by the kinases ERK1/2 (e.g. 
P-X-Ser/Thr-X). Therefore, we checked whether this phosphorylation was directed by ERK, by expressing 
the kinase-dead mutant form of ERK1 or ERK2 (Figure 5C). As previously, the dominant negative mutants 
inhibited endogenous ERK1/2 activities (reduced p-p90 RSK level). However, they failed to prevent 
Thr421/Ser424 phosphorylation of p70S6K upon MEK1/2 activation. In contrast, their expression was 
sufficient to restore partially the phosphorylation of p70S6K and S6 in ERK2-silenced cells (Figure 5D). 
Full activation of the p70S6K protein is dependent on phosphorylations of multiple Thr and Ser residues, 
which are regulated by successive actions of different kinases, depending on the cell type and stimulus 
(Fenton and Gout, 2011). The main regulator of p70S6K activity is the complex mTORC1 which includes 
the proteins mTOR (mammalian Target Of Rapamycin), Raptor and GβL (Kim et al., 2003). As ERK1/2 
has been shown to activate mTORC1 both directly and indirectly (Carriere et al., 2011; Ma et al., 2005), we 
then tested the involvement of this complex in MEKinduced p70S6K activation. The chemical inhibition of 
mTOR by rapamycin did not inhibit the p70S6K phosphorylation on Thr421/Ser424 whereas Thr389 one 
was totally abolished (Figure 5E). Other proteins and notably the kinases PDK1, Akt and the conventional 
PKCs have been shown to regulate p70S6K activation (Iijima et al., 2002; Magnuson et al., 2012). 
However, the phosphorylation of Thr421/Ser424 induced by active mutant of MEK1/2 did not involve 
those kinases as chemical inhibition of PDK1 by GSK2334470 (GSK), PI3K by wortmannin or PKCs by 
GF109203X (GFX) did not modify the level of p70S6K phosphorylation (Figure 5E). The kinase mTOR 
could also act in another complex named mTORC2 (mTOR, Rictor, mLST8) which has been initially 
described as rapamycin-insensitive (Sarbassov et al., 2004). Thus, in order to test the involvement of this 
complex, mTOR expression was directly silenced by shRNA in Huh-7 cells. As shown in Figure 5F, the 
loss of mTOR completely abrogated p70S6K phosphorylation on Thr389, both in control and in MEK1/2-
DD expressing cells. Nevertheless, phosphorylation on Thr421/Ser424 was not totally impacted by the 
inhibition of mTOR. Hence, these data show that ERK could stimulate p70S6K phosphorylation on 
Thr421/Ser424, independently of its kinase activity and of the activation of PDK1-, PI3K/Akt/mTOR- and 
PKC pathways. 
To study the requirement of p70S6K in MEK/ERK induced growth arrest, we next knocked-down its 
expression by shRNA and analyzed the proliferative capacities of cells. RNAi-mediated decrease of 
p70S6K activity did not strongly modify ERK1/2 activation but it completely prevented the expression of 
the cell cycle inhibitor p21 induced upon MEK activation (Figure 6A) or upon HGF treatment 
(Supplementary Figure 2). Consequently, p70S6K-silenced cells were less subjected to the growth arrest 
induced by active forms of MEK1/2 than control cells (Figure 6B). As p70S6K could act in the regulation 
of protein synthesis as well as in regulation of gene transcription, we next investigated which steps of p21 
induction was dependent on p70S6K activity. By quantitative PCR analysis, we observed that sustained 
ERK activity enhanced CDKN1A gene transcription. Indeed, a 4 to 6 fold induction of p21 mRNA could 
be seen in MEK1/2-DD expressing cells and interestingly, this induction persisted and was not altered 
when p70S6K was transiently silenced (Figure 6C). Hence p70S6K regulated p21 expression at a post-
transcriptional level. The cell cycle inhibitor p21 exhibits a short halflife and thus requires different 
phosphorylation events to be stabilized (Child and Mann, 2006). We thus investigated whether p70S6K 
could regulate p21 stability. To induce p21 expression, Huh-7 cells were first treated with sodium butyrate, 
a HDAC inhibitor, for 24h and protein translation was then blocked with cycloheximide for different times. 
The expression of p21 was finally monitored by western blot. As shown in Figure 6D, neither the 
expression of active MEK1 nor the silencing of p70S6K modified p21 stability. In all cases, p21 exhibited a 
half-life of about 45 minutes, suggesting that p70S6K did not regulate p21 at this level. Finally, due to the 
central position of p70S6K in the regulation of protein biosynthesis, we analyzed if the kinase could 
regulate p21 protein translation. For this purpose, we monitored p21 protein accumulation following 
proteasome inhibition. As p70S6K did not regulate p21 stability, this accumulation could be seen as a 
reflection of the protein translation efficiency. In this setting, we observed that the p21 level increases more 
rapidly in control cells than in Huh-7 cells stably knocked-down for p70S6K (Figure 6E). Interestingly, this 
slower accumulation seems not to be specific to p21 and it could also be observed with c-Myc oncogene 
whereas p27 and p53 showed same translation rate in control cells as in p70S6K-silenced cells. 
Finally, we wanted to know whether the requirement of p70S6K for the MAPK-mediated growth arrest was 
restricted to Huh-7 cells or could be observed in other tumor cell lines. As shown in Figure 7, expression of 
active forms of MEK1/2 triggered p70S6K phosphorylation on Thr421/Ser424 and p21 expression in 
HepG2 cells, another human hepatocellular carcinoma cell line. Indeed, we noticed that p21 expression was 
also dependent, in these hepatic cells, on p70S6K activity as silencing of the kinase reduced both basal and 
induced expression of the cell cycle inhibitor (Figure 7A). Furthermore, we also observed that p70S6K 
requirement for MAPK-induced growth arrest was not restricted to liver cancer as similar conclusions 
could be made on the human breast cancer cell line MCF-7 (Figure 7B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
In the present study, we have shown that aberrant activation of ERK1/2 kinases could impede cellular 
growth by simultaneously increasing p21WAF1 gene transcription and enhancing its protein synthesis via a 
p70S6K-dependent mechanism. We also demonstrated that the kinases ERK1 and ERK2 could both 
participate in the MAPK-mediated growth arrest in a redundant manner and independently of their kinase 
activity. 
 
Functional specificities of MAPKs- With more than 85% of amino acid homology, the kinases MEK1 and 
MEK2, as well as ERK1 and ERK2, have been considered for a long time as fully redundant proteins 
(Shaul and Seger, 2007). However, several studies, including those of our team, have shown that these 
kinases were not totally interchangeable. First, MEK1 and MEK2 can be differently regulated. Indeed 
MEK1 can undergo a negative feedback mediated by ERK2 via the phosphorylation of its Thr292 residue, 
a regulatory site lacking in MEK2 protein (Eblen et al., 2004). Furthermore, MEK1 but not MEK2 can bind 
to the scaffold protein MP1 (Schaeffer et al., 1998) and can be activated by the A-Raf kinase (Wu et 
al., 1996), suggesting that different protein affinities could exist. Second, functional differences have been 
demonstrated in vitro or in vivo following the specific extinction of MEK isoform. For instance, MEK1 
gene invalidation in mice is lethal at the embryonic stage unlike MEK2 knock-out, revealing an 
predominant role for MEK1 in the development of extraembryonic tissues (Belanger et al., 2003; Giroux et 
al., 1999; Nadeau et al., 2009). Here, we demonstrated an absolute requirement of MEK1 but not MEK2 for 
the proliferation of hepatocarcinoma cells. MEK1 silencing suppressed the growth of Huh-7 cells and 
MEK2 overexpression could not compensate for the loss of MEK1. Moreover, expression of a dominant 
negative form of MEK1, but not MEK2, decreased Huh-7 cell proliferation. Two different studies have 
convincingly demonstrated that the apparent specificity of the kinases ERK1 and ERK2 in fibroblast 
proliferation actually reflected their difference of expression (Lefloch et al., 2007; Voisin et al., 2010). For 
their authors, the specific role of ERK2 seen in the proliferation of many tumor models is related to the 
higher expression level of ERK2. Therefore ERK2 silencing has a greater impact on ERK total activity than 
ERK1 extinction and thus will give more severe phenotype. This gene dosage effect could also be found in 
this study. Indeed, Huh-7 cells express more ERK2 proteins than ERK1, as noticed by western blot using 
anti-phospho-ERK1/2 antibody. As a consequence, ERK2 silencing, but not ERK1, totally blocked p21 
induction and the growth-inhibitory signal upon MEK activation. Nevertheless, kinase-dead form of ERK1 
could restore p21 induction in ERK2-silenced cells, demonstrating that ERK1 and ERK2 are both involved 
in MAPK-induced growth arrest of Huh-7 cells. Same conclusions have been made by Hong et al. in others 
tumor cell lines (Hong et al., 2009). 
Regarding the MEK1/2 functional specificity observed here, we demonstrated that the targeting of MEK1 
but not MEK2 inhibited hepatocarcinoma cell proliferation. However in human or mouse tissues, and 
notably in liver, MEK2 exhibits a higher expression level than MEK1 (Pelech, 2006). Similarly, we 
observed that MEK2 overexpression could not compensate for the loss of MEK1. Thus MEK1 dependence 
of Huh-7 cells for proliferation seemed not to be a simple gene dosage effect but instead a specific role of 
MEK1 may exist in these highly differentiated cells. A specific requirement of MEK1 has also been 
observed in the proliferation of different cell models (Scholl et al., 2009; Shama et al., 2008; Ussar, 2004). 
Nevertheless, it is to note that the functional specialization of MEK1 and MEK2 seems to be dependent on 
cell type since predominant roles of MEK2 over MEK1 have also been underlined in other models (Lee et 
al., 2011; Voisin et al., 2008). Moreover, MEK1 and MEK2 could have both redundant and specific roles in 
a same cell type and the notion of functional specificity could thus be dependent on the stimulus type, 
duration and/or activated signaling cross-talks (Lee et al., 2011). 
 
ERK1/2-dependent phosphorylation of p70S6K in growth arrest signaling- In this study, we showed that 
expression of active mutant of MEK1 or MEK2 was sufficient to inhibit the proliferation of human 
hepatocellular carcinoma cells. By RNAi experiments, we also demonstrated that this growth arrest was 
linked to the sustained activity of the ERK1/2 kinases and the subsequent induction of cycle inhibitor 
p21WAF1. Similar results were obtained on normal hepatocytes. Indeed, we have previously shown that the 
inability of rat hepatocytes to undergo multiple division cycles in primary culture was linked to a ERK2-
dependent induction of p21WAF1 (Frémin et al., 2009). Moreover, sustained stimulation of MEK/ERK 
activities by the cytokine hepatocyte growth factor (HGF) inhibited the in vitro proliferation of different 
models of human hepatocellular carcinoma (HepG2, Hep3B, Huh-7) and this has also been linked to the 
induction of p21WAF1 by the MEK/ERK pathway (Shiota et al., 1992; Shirako et al., 2008; Tsukada et al., 
2001). In addition, we showed here that this growth arrest could be mediated by a non-catalytic function of 
the ERK kinases. Indeed, ERK1/2 kinase-dead mutants could not suppress p21 induction upon MEK 
activation while blocking endogenous ERK activities (e.g. reduced phospho-p90 RSK level). Moreover, 
expression of these mutants in ERK2-silenced cells was sufficient to restore p21 induction by active 
MEK1/2. Even if we cannot totally exclude that the ERK kinase-dead mutants harbored a weak residual 
activity and did not absolutely demonstrate that the mutants have no activity, these results are consistent 
with a possible non-catalytic function of ERK as previously described in the MAPK-induced growth arrest 
(Hong et al., 2009). Moreover, we showed that besides the transcriptional regulation of p21WAF1, the 
sustained activation of the MEK/ERK pathway could stimulate the translation of the cell cycle inhibitor by 
allowing the activation of the kinase p70S6K.  
The full activation of p70S6K requires phosphorylations of various residues and notably phosphorylations 
of its Cterminal autoinhibitory pseudosubstrate domain (Ser411, Ser418, Thr421 and Ser424) and different 
critical sites like Thr389 (Fenton and Gout, 2011). In MEK1/2-DD expressing cells, we noticed an 
important phosphorylation of the Thr421 and Ser424 sites and only a small increase in the Thr389 
phosphorylation. This suggests that the latter phosphorylation seemed to be mediated by a kinase different 
from ERK1/2. Several kinases have been implicated in the regulation of p70S6K activation. Depending on 
the cell type, an involvement of PDK1, mTOR, PI3K or PKC kinases was observed (Iijima et al., 2002; 
Laser et al., 1998; Magnuson et al., 2012). Here, we showed that phosphorylation of Thr421/Ser424 
residues was not dependent on these kinases but on ERK1/2 functions, since only ERK2 silencing 
prevented the phosphorylation of these sites. Nevertheless, we noticed that Thr389 phosphorylation was 
dependent on a PDK1/PI3K/mTOR pathway. Similarly, it has been shown in neutrophils that the cytokine 
granulocyte macrophage colony-stimulating factor (GM-CSF) triggered a mTOR-dependent 
phosphorylation of Thr389 of p70S6K concurrently with a ERK-dependent phosphorylation of 
Thr421/Ser424. Both phosphorylations were required for full activation of p70S6K kinase (Lehman et al., 
2003). ERK-induced phosphorylation of p70S6K on Thr421/Ser424 has also been observed in other models 
like cardiac muscle cells, epithelial cell or CD8 T-cells (Iijima et al., 2002; Salmond et al., 2009; Zhang et 
al., 2001). Hence, ERK sustained activation could firmly participate to activate p70S6K, in addition to the 
PI3K/PDK1/Akt/mTOR dependent phosphorylation of Thr389. 
Nevertheless and despite the fact that Thr421/Ser424 residues are localized in a consensus sequence for 
ERK phosphorylation (PX[T/S]P), we demonstrated here that ERK-mediated p70S6K activation was 
regulated by a non-catalytic function of ERK1/2. First ERK deletions by shRNA, but not dominant 
negative form of ERK, reduced Thr421/Ser424 phosphorylation upon MEK activation. Second, ERK1/2 
kinase-dead mutant expression could restore p70S6K phosphorylations on autoinhibitory domains in 
ERK2-silenced cells. Two different studies have shown that ERK1/2 could interact with p70S6K in cells 
(Gu et al., 2000; Lehman and Gomez-Cambronero, 2002). Hence, one could speculate that ERK1/2 could 
act as a scaffold protein to promote the activity of an unknown kinase on p70S6K. Alternatively, the 
interaction between ERK and p70S6K could mask the C-terminal domain of p70S6K, preventing 
phosphatase action on Thr421/Ser424.  
Finally, we have shown that p70S6K activity was important for MEK1/2-DD-induced growth arrest 
because its silencing inhibited p21WAF1 expression. We also demonstrated that p70S6K was not required to 
stimulate CDKN1A gene transcription or to increase p21 protein stability but to enhance the translation of 
p21 mRNA. Indeed, p21 protein accumulated less efficiently in p70S6K-deficient cells than in control 
cells, following proteasome inhibition. Due to the short half-life of the protein, the regulation of p21 
translation could thus represent an important mechanism to regulate the expression of this cell cycle 
inhibitor and thus the cellular growth. These results are consistent with the well-defined function of 
p70S6K in the regulation of protein synthesis (Mamane et al., 2006) and with different studies showing a 
role of the mTOR/p70S6K pathway in DNA-damage- or mitogen-induced p21 expression (Beuvink et al., 
2005; Gaben et al., 2004). Indeed, using rapamycin or its derivate RAD001, those studies have evidenced a 
role of the mTOR/p70S6K pathway in the control of p21 translation. No modulations of the transcription or 
of the stability of p21 were seen. However, for one study, the translational regulation was selective to p21 
and for the other one, it was a global effect. Here, we noticed that the effect of p70S6K was not selective to 
p21 as it has also been observed for the protein c-Myc. However, p27 and p53 protein accumulations 
following proteasome inhibition were not modified by the loss of p70S6K. Given the fact that these latter 
proteins contain an IRES element, contrarily to p21 (Kannan-Thulasiraman et al., 2008; Miskimins et al., 
2001; Ray et al., 2006), we hypothesize that p70S6K could be only required to enhance cap-dependent 
translation of proteins but further studies will be required to explore this assumption. Moreover, we suggest 
that in the mTOR/S6K pathway, the kinase p70S6K played a major role in the control of p21 translation as 
we showed that mTOR inhibition did not suppress p21 induction upon MEK activation contrarily to 
p70S6K targeting. 
In conclusion, we have shown that the sustained activation of the kinases ERK1 and ERK2 stimulated 
p70S6K phosphorylation on Thr421/Ser424 in a redundant and non-catalytic manner and that this 
activation was required to stimulate cap-dependent translation of the p21 and subsequent growth arrest. 
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FIGURE LEGENDS 
 
FIGURE 1. Constitutive activation of MEK1 or MEK2 inhibits Huh-7 cell proliferation. The 
proliferation of Huh-7 cells expressing wild-type (WT), kinase-dead (K) or mutant active (DD) form of 
MEK1 (A) or MEK2 (B) was assessed by MTT assays. Results are expressed as relative units (RU). (C) 
ERK1/2 activation status was monitored by western blot in Huh-7 cells expressing wild-type or mutant 
forms of MEK1/2. Data are representative of at least three independent experiments. (Mean ± SD; * 
P<0.05; ** P<0.01) 
 
FIGURE 2. MEK1 but not MEK2 is required for cell proliferation. The growth rates of Huh-7 cells 
stably knocked-down for MEK1 or MEK2 (A) or Huh-7 cells transiently silenced for MEK1 and 
expressing wild-type (WT) or mutant active (DD) form of MEK1 (B) or MEK2 (C) were assessed by 
MTT assays (right panels). Results are expressed as relative units (RU). In each case, the efficiency of 
MEK1 or MEK2 silencing and plasmid expression was monitored by western blot (left panel). Data are 
representative of at least three independent experiments. (Mean±SD;* P<0.05;** P<0.01) 
 
FIGURE 3. Growth arrest induced by the MEK/ERK pathway involves p21 expression. (A) The 
expression of different cell cycle regulators was analyzed by western blot in Huh-7 cells expressing 
wildtype (WT), kinase-dead (K) or mutant active (DD) form of MEK1 or MEK2. Expression of MEK1 or 
MEK2 constructs was verified by immunobloting with anti-HA antibody. (B) Huh-7 were transfected with 
His-p21 construct and selected by puromycin. The expression of His-tagged p21 was analyzed by western 
blot (upper panel) and the proliferation rate of selected cells was assessed by MTT assay (lower panel). 
(C) Comparison of the proliferation rate between Huh-7 cells expressing ectopic p21WAF1, active mutant 
form (DD) of MEK1 or MEK2 and controls cells. Results are expressed as percent of control cell 
proliferation. Data are representative of at least three independent experiments. (Mean ± SD; ** P<0.01) 
 
FIGURE 4. ERK1 and ERK2 inhibit Huh-7 cells growth in a redundant and non-catalytic manner. 
(A) Huh-7 were transiently transfected with shRNA targeting ERK1 (shERK1), ERK2 (shERK2) or 
scramble sequence (shCtl), concomitantly with an active mutant form of MEK1, MEK2 or empty vector. 
Expression of HA-tagged MEK1 and MEK2 constructs and the induction of the cell cycle inhibitor 
p21WAF1 was analyzed by western blot. Densitometric analysis were performed to measure p21 induction 
and results were expressed as relative units (RU) (right panel). (B) The growth arrest induced by active 
mutant form of MEK1 (pMEK1DD) or MEK2 (pMEK2DD) was evaluated in Huh-7 cells transiently 
silenced for ERK1, ERK2 or in control cells. Results are expressed as percentage of proliferation 
inhibition, as described in Materials and Methods section. (C-D) The induction of p21 by active MEK1/2 
was analyzed by western blot in Huh-7 cells expressing kinase-dead mutant form of ERK1 (K71R) or 
ERK2 (K52R) (C) or transiently silenced for ERK2 and expressing the ERK mutant protein (D). Data are 
representative of at least three independent experiments (Mean±SD;* P<0.05;** P<0.01). 
 
FIGURE 5. ERK1/2 sustained signaling promotes p70S6K activation independently of their kinase 
function. (A) The effects of constitutive activation of MEK1 and MEK2 on various signaling pathways 
were analyzed in Huh-7 cells by western blot. (B) Huh-7 cells expressing active mutant (DD) form of 
MEK1/2 or empty vector were transiently silenced or not by shRNA for ERK2 and phosphorylation status 
of p70S6K was then analyzed by western blot. (C-D) p70S6K activation by active MEK1/2 (MEK1/2DD) 
was studied by western blot in Huh-7 cells expressing kinase-dead mutant form of ERK1 (K71R) or 
ERK2 (K52R) (C) or transiently silenced for ERK2 and expressing the ERK mutant protein (D). (E) Huh- 
7 cells expressing active form of MEK1/2 or empty vector were treated for 2h with DMSO, GSK2334470 
(GSK; 1 µM), GF109203X (GFX; 2 µM), Rapamycin (10 nM) or Wortmannin (500 nM). Activation of 
p70S6K was then analyzed by western blot. (F) Huh-7 cells expressing active mutant form of MEK1/2 or 
empty vector were transiently silenced by shRNA for mTOR. Phosphorylation status of p70S6K was then 
analyzed by western blot. For all these experiments, MEK1/2-DD expression was monitored by 
immunoblotting with anti-HA or anti-P-ERK antibody. Data are representative of at least three 
independent experiments. 
 FIGURE 6. p70S6K is required for the growth arrest induced by the MEK/ERK pathway. Huh-7 
expressing active mutant form of MEK1 or MEK2 were transiently transfected with shRNA targeting 
p70S6K or scramble sequence (shCtl). The induction of the cell cycle inhibitor p21WAF1 was then analyzed 
by western blot (A) and the growth arrest induced by MEK1/2-DD was assessed by MTT assays (B). 
Results are expressed as percentage of proliferation inhibition, as described in Materials and Methods 
section. (C) Total mRNA were submitted to RT-qPCR to determine p21WAF1 expression. Data were 
normalized relatively to the expression level found in control cells. (D) Huh-7 cells expressing mutant 
active MEK1 (MEK1-DD) or empty vector were transfected with shCtl or shRNA for p70S6K. Cells were 
treated for 24h with sodium butyrate (10 mM) to induce p21 expression and next with cycloheximide (20 
µM) for indicated times. Expression of p21 was analyzed by western blot (upper panel) and p21 half-lives 
were calculated after densitometric analyses (lower panel). As sodium butyrate treatment led to different 
rate of p21 induction, p21 blot exposition was different between the three conditions. Results are 
expressed as relative units (RU). (E) Huh-7 stably knocked-down for p70S6K or control cells were treated 
with MG132 (10 µM) for indicated times and accumulation of different proteins were monitored by 
western blot (left panel). p21, p27 and c-Myc expression were calculated after densitometric analyses and 
expressed as relative units (RU) (right panel). Data are representative of at least three independent 
experiments. (Mean ± SD; * P<0.05). 
 
FIGURE 7. p70S6K requirement for MAPK-induced growth arrest is not restricted to Huh-7 cells. 
HepG2 (A) and MCF-7 (B) cells expressing active form of MEK1/2 (MEK1/2-DD) or empty vector were 
transiently silenced or not by shRNA for p70S6K. p21 expression and p70S6K phosphorylation status 
were then analyzed by western blot (left panel). p21 expression were calculated by densitometric analyses 
(right panel) and results expressed as relative units (RU). Data are representative of at least three 
independent experiments. (Mean ± SD; * P<0.05; ** P<0.01). 
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